ERBB2 and breast carcinoma: Similarly, Fimereli and colleagues did not preselect their breast cancer cohort for TNBC patients and observed that the number of fusion genes per sample ranged between 0 and 31 with a mean of 6.7 fusion genes, noting the highest prevalence in HER2-positive tumors, which were not part of our study (Fimereli et al. 2018).